

Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Immune Activity of Sweet Potato (*Ipomoea batatas* L.) Glycoprotein after**
2 **Enzymatic and Chemical Modifications**

3 Xuejuan Xia,^a Guannan Li,^b Jiong Zheng,^{a,c} Jinsong Wu^a and Jianquan Kan^{*a,c}

4

5 ^a College of Food Science, Southwest University, Chongqing 400715, China

6 ^b College of Biotechnology, Southwest University, Chongqing 400715, China

7 ^c Laboratory of Quality & Safety Risk Assessment for Agro-products on Storage and
8 Preservation (Chongqing), Ministry of Agriculture, 400715, China

9

10 ***Corresponding author: Jianquan Kan**

11 College of Food Science

12 Southwest University

13 Tiansheng Road 1, Chongqing, 400715

14 PR China

15 Tel.: +86 23 68 25 03 75

16 Fax: +86 68 25 19 47

17 E-mail: kanjianquan@163.com

18 **Abstract:** This study aims to investigate the immune activity of sweet potato
19 (*Ipomoea batatas* L.) glycoprotein (SPG-1) before and after enzymatic and chemical
20 modifications. The protein portion of SPG-1 was modified by pepsin, trypsin, and
21 acetylation treatments. The carbohydrate portion was modified by glucoamylase,
22 NaIO₄, and sulfation treatments. The carbohydrate chain of SPG-1 (SPG-1-C) was
23 obtained. Immune activity was analyzed by measuring the serum lysozyme activity
24 and T cell immune response. SPG-1 increased immune activity with a dose-response
25 effect. Immune activity was slightly decreased after pepsin and trypsin hydrolysis,
26 while increased after moderate degree (DS = 0.68) of acetylation. Immune activity
27 was partly decreased after glucoamylase hydrolysis, remarkably decreased after
28 NaIO₄ oxidation, or even loss after high modification by sulfation. Compared with
29 SPG-1 groups, SPG-1-C groups increase immune activities with insignificant ($P >$
30 0.05) differences. Hence, appropriate modifications of protein portion could be
31 conduct and high modifications of carbohydrate portion should be avoided to improve
32 or maintain the immune function of SPG-1.

33

34 **Keywords:** Sweet potato glycoprotein; modification; carbohydrate chain; immune
35 activity

36

37 Introduction

38 The industrial production of glycoprotein has developed rapidly owing to its various
39 important bioactivities,¹ such as hypolipidemic activity,² hypoglycemic activity,³
40 immunity,⁴ anticancer,⁵ and antioxidant.⁶ As potential raw materials of glycoprotein
41 production, sweet potatoes (*Ipomoea batatas* L.) are one of the most important
42 economic crops in many tropical and subtropical countries in Asia, Africa, and Latin
43 America. China shares approximately 90% of sweet potato production worldwide,
44 with an annual production 117 million tons.⁷ Therefore, studies on sweet potato
45 glycoprotein (SPG) are important.

46 Some bioactivities of SPG have being found out. In our previous study,² we found
47 that SPG exhibits dose-dependent hypolipidemic effect. Ozaki *et al.*⁸ and Oki *et al.*⁹
48 found that an arabinogalactanprotein (WSSP-AGP) from white-skinned sweet potato
49 has hypoglycemic effects. Recent years, several methods, such as genetic, physical,
50 chemical, and enzymatic modifications, have been introduced to improve the
51 functional properties and technological applications of glycoproteins.¹⁰ Thus, it is
52 necessary to study the relationship between the structure and activity of SPG.

53 This study was conducted to determine the immune activity of SPG-1 after
54 enzymatic and chemical modifications. Considering that functions may be dependent
55 on either the protein or carbohydrate portion or on both.¹¹ Pepsin, trypsin, and
56 acetylation treatments were conducted to modify the protein portions of SPG-1.
57 Simultaneously, glucoamylase, NaIO₄, and sulfation treatments were conducted to
58 modify the carbohydrate portions. Furthermore, its carbohydrate chain (SPG-1-C) was

59 obtained. Serum lysozyme activity and T cell immune response of SPG-1, modified
60 SPG-1, and SPG-1-C were examined. The study should be able to provide theoretical
61 insights for future improvements in SPG-1 manufacture process.

62

63 **Materials and methods**

64 **Materials and animals**

65 Sweet potato (*I. batatas* L. var. Beijing no. 2) was harvested and identified at the
66 Department of Botany, College of Horticulture, Southwest University, Chongqing,
67 China.

68 Male and female 8- to 10-week old BALB/c mice (18–20 g) were obtained from the
69 animal center of Chongqing Medical University. All experimental protocols were
70 approved by the Ethics Committee of Chongqing Medical University (Reference
71 number: 24301035). The mice were acclimatized for 2–3 days prior to the experiment.
72 During the experiment, the mice were fed under controlled environmental conditions
73 (25 ± 1 °C temperature; normal day/night cycle; and 55% to 60% humidity). The mice
74 were provided with basal diet and free access to drinking water. All conditions and
75 handling of the animals were conducted according to the International Guiding
76 Principles for Biomedical Research Involving Animals.¹²

77

78 **Physicochemical Properties of SPG-1**

79 Isolation, purification, total carbohydrate content, protein content, and molecular
80 weight determinations of SPG-1 were conducted in our previous study.²

81 To study amino acid composition of SPG-1, the β -elimination reaction was
82 performed according to the methods described by Chen *et al.*¹³ with some
83 modifications. SPG-1 (2 mg) was dissolved in 0.1 mol/L NaOH, 1.0 mol/L NaBH₄
84 solution; the reaction was conducted at 37 °C for 72 h and terminated with addition of
85 25% (v/v) acetic acid. The amino acid composition and absorbance of the solutions
86 before and after β -elimination were determined with a Hitachi 835 amino acid
87 analyzer (Hitachi Co., Japan) at 240 nm.

88

89 **Modification of SPG-1**

90 ***Protease (Pepsin and Trypsin) Treatments***

91 SPG-1 was dissolved in distilled water and hydrolyzed separately by pepsin (P7000,
92 from porcine gastric mucosa, powder, \geq 250 units/mg solid; Sigma) and trypsin
93 (T4799, from porcine pancreas, powder, 1,000-2,000 BAEE units/mg solid; Sigma),
94 under optimized conditions (pH 1.5/37 °C for pepsin and pH 8.0/37 °C for trypsin).¹⁴
95 Protease digestions were conducted according to the methods described by Kim *et*
96 *al.*¹⁵ with modifications. The pH of the solutions was adjusted with 1.0 mol/L NaOH
97 or 1.0 mol/L HCl prior to and during hydrolysis. The digests with different enzyme
98 concentrations (2.0 and 5.0 g/100 mL) were incubated for different duration (1, 2, 3, 4,
99 and 5 h). Afterward, the pH of the solutions were adjusted to 7.0, the solutions were
100 dialyzed against deionized water for 24 h, precipitated, dried, and stored at -20 °C.

101

102 ***Glucoamylase Treatment***

103 SPG-1 hydrolysis with glucoamylase (A7420, from *Aspergillus niger*, lyophilized

104 powder, 30-60 units/mg protein (biuret), \leq 0.02% glucose; Sigma) was conducted
105 according to the method described by Bailey and MacRae¹⁶ with some modifications.
106 SPG-1 was dissolved in sodium acetate-acetic acid buffer (0.2 mol/L, pH 4.5) and
107 hydrolyzed with two concentrations (0.1 and 0.15 g/100 mL) of glucoamylase at
108 60 °C for 1, 2, 3, 4, and 5 h. Afterward, the pH of the solutions were adjusted to 7.0,
109 and the reaction mixtures were then cooled, dialyzed, precipitated, dried, and stored at
110 -20 °C.

111

112 *NaIO₄ Treatment (Periodate Oxidation)*

113 SPG-1 was also oxidized with NaIO₄ solution to release the aldehyde group of the
114 sugar moiety. The NaIO₄ oxidation was conducted according to the method described
115 by Wang *et al.*¹⁷ with some modifications. SPG-1 (100 mg) was oxidized with 100 mL
116 of 0.35 mol/L NaIO₄ (31148, ACS reagent, \geq 99.8%; Sigma) at 18 °C in the dark.
117 The absorbance of the reaction mixture at 223 nm was monitored daily until it
118 stabilized (about 108 h). The reaction was terminated with 2 mL ethylene glycol, and
119 the reaction mixture was then dialyzed against deionized water for 24 h, precipitated,
120 dried, and stored at -20 °C.

121

122 *Acetylation Treatment*

123 Acetylated SPG-1 was prepared following the methods of Kumar *et al.*¹⁸ with some
124 modifications. A 20% (w/v) glycoprotein suspension was prepared by dissolving 1 g
125 of SPG-1 in distilled water. The pH of the solution was adjusted to 8.0–8.5 with
126 1.0 mol/L NaOH, and the slurry was stirred magnetically for 30 min at room
127 temperature. Various amounts of acetic anhydride (0.8, 1.6, and 2.4 g) were then
128 added dropwise to the uniformly mixed suspension to obtain three different (low,

129 medium and high) degrees of substitution. The stirring continued for 180 min, while
130 maintaining the pH between 8.0 and 8.5. Afterward, the pH of the solution was
131 adjusted to 7.0 with 0.5 mol/L HCl, and the reaction mixture was dialyzed against
132 deionized water for 72 h, precipitated, dried, and stored at -20°C . The degree of
133 substitution (DS) of the acetylated SPG-1 was then determined by the method of
134 Wurzburg.¹⁹

135

136 ***Sulfation Treatment***

137 Sulfated glycoprotein was prepared according to the method described by Inoue *et*
138 *al.*²⁰ with slight modifications. 1.0 g SPG-1 was suspended in 8 mL of formamide,
139 and added with 4 mL of varying ratios of sulfation reagent (chlorosulfonic
140 acid:pyridine solution = 1:2, 1:1, and 2:1, v/v) to obtain three different (low, medium
141 and high) degrees of substitution. Stirred magnetically for 1 h, cooled, and added with
142 8 mL of distilled water and 15 mL of 2.5 mol/L NaOH. The reaction mixture was then
143 dialyzed against deionized water for 72 h, precipitated, and dried to obtain a white
144 sample. The DS was determined following the method of Doigson and Price.²¹

145

146 **Isolation and Purification of SPG-1-C**

147 SPG-1-C was isolated after β -elimination reaction of SPG-1. After deproteinating the
148 aqueous solution using the Sevag method,²² the supernatant was collected and
149 dialyzed against a flowing clean water for 72 h, and then against distilled water for 24
150 h using a dialysis bag with 1,000 Da molecular-weight cut-off (Sigma). The eluted
151 solution was characterized at 280 nm using T6 UV and visible spectrophotometer
152 (Beijing Persee General Instrument Co., China) to ensure that no protein or amino

153 acid was left.¹¹ Fehling's solution was used to ensure that no monosaccharide was
154 left.²³ The trapped fluid was mixed with distilled water and purified on a
155 DEAE-cellulose-52 anion-exchange column (2.6 cm × 50 cm; Whatman, England)
156 with a gradient of NaCl solution (0.0–3.9 mol/L) as eluting solvent at 1.6–1.7 mL/min
157 flow rate.²⁴ The carbohydrate content of every 5 mL of eluted solution was
158 determined at 490 nm according to phenol-sulfuric acid method.²⁵ After dialysis, the
159 trapped fluid was precipitated with four volumes of absolute ethanol, mixed, kept
160 overnight in a refrigerator at 4 °C, and centrifuged (5810; Eppendorf, Germany) at
161 5000 *g* for 5 min. The precipitate was washed twice with ethanol and acetone²⁶ to
162 obtain the crude SPG-1-C prior to vacuum drying at 40 °C (Shanghai Yuejin Medical
163 Apparatus Factory, China).

164 The crude sample was dissolved in distilled water and further purified using
165 Sephadex G-100 gel filtration column (1.6 cm × 100 cm; Pharmacia, Sweden) and
166 distilled water as eluting solvent at 0.5 mL/min flow rate.²⁷ The absorbance of the
167 eluted solution was determined at 490 nm, and then dialyzed, precipitated, and dried.
168 The purity of SPG-1-C was confirmed by a Sepharose CL-6B gel filtration column
169 (1.6 cm × 100 cm; Sigma, America) using 0.02 mol/L Tris-HCl buffer (pH 7.2) as
170 eluting solvent at 0.5 mL/min flow rate.

171 Furthermore, HPLC method was used to reconfirm the purity and determine the
172 molecular weight of SPG-1-C. Agilent 1200 HPLC system (Agilent, USA) with gel
173 permeation chromatography (GPC) on a TSK-G2000SW column (TOSOH
174 Corporation, Japan) was used based on the method developed by Li *et al.*¹ Dextran

175 standards (T-500 $M_w=500,000$; T-110 $M_w=110,000$; T-70 $M_w=70,000$, T-40
176 $M_w=40,000$ and T-10 $M_w=10,000$; Amersham Pharmcia, Sweden) were used to
177 establish a standard curve (Wang et al., 2013). Finally, a calibration curve was
178 prepared from the known M_w Dextran T system standard:
179 $\lg \overline{M_w} = 8.6099 - 0.2858RT$ ($r=0.9736$, RT: retention time).

180

181 **Serum Lysozyme Activity**

182 The BALB/c mice were randomly divided into groups with 10 animals in each group.
183 The experimental groups were treated with following doses: 50 and 80 mg/kg-d of
184 SPG-1; 80 mg/kg-d of modified SPG-1; 50 and 80 mg/kg-d of SPG-1-C. A similar
185 volume of normal saline was administered to the normal control (NC) group. The
186 drugs were given by gavage once a day for 10 days. A day after the last day of drug
187 administration, the mice were lightly anaesthetized under ether, and blood samples
188 were taken from their eye sockets. The serums were separated by centrifugation at
189 4000 g for 5 min and stored at -20°C for the lysozyme activity measurements.²⁸

190 Lysozyme activity in mice serums was determined by agar diffusion plate method
191 as described by Yin *et al.*²⁹ A series of lyophilized hen egg-white lysozyme (HEWL,
192 Sigma) standards (0, 5, 25, 100, and 500 mg/L) were prepared in phosphate/citrate
193 buffer (0.067 mol/L, pH 6.4). A suspension of 50 mg to 100 mg of *Micrococcus*
194 *lysodeikticus* (ATCC 4698, Sigma Chemical, Germany) in 100 mL of buffer was
195 freshly prepared on the assay day. Briefly, 10 × 10 cm 4 mm agar plates with 0.5–
196 1.0 g/L *M. lysodeikticus* were carefully prepared. Circular holes (2 mm) were cut and

197 filled with 25 μ L of the samples. After incubation at 25 $^{\circ}$ C for 18 h, the diameters of
198 the zones inhibition (transparent zone) around the holes with sample and HEWL
199 standards were measured.

200

201 **T Cell Immune Response**

202 The standard lymphocyte transformation test (LTT) described by vonBaehr *et al.*³⁰
203 was used to determine the T cell immune response of the samples. Peripheral-blood
204 mononuclear cells were isolated from the heparinized venous blood of normal human
205 volunteers by density-gradient centrifugation (Ficoll-Paque, Pharmacia, Sweden). Up
206 to 0.1 mL mononuclear cell fraction was suspended in 1.0 mL RPMI 1640 culture
207 medium with penicillin (100 μ g/mL), streptomycin (100 μ g/mL), L-glutamine
208 (200 μ g/mL), sodium bicarbonate (7.5%, w/v), and calf serum (10%, v/v). Up to
209 0.05 mL of sample or culture medium (control group) was added to the mixture and
210 incubated for 27 $^{\circ}$ C for 48 h. For the final 24 h of culture incubation, 1 mCi/mL 3 H
211 thymidine (Amersham, UK) was added to the mixture. The cells were then harvested
212 onto glass-fiber filters (Wallac, Sweden) and counts per minute (cpm) of the
213 incorporated 3 H thymidine activity were determined using a beta-counter (Wallac,
214 Sweden).

215

216 **Statistical Analyses**

217 The results were expressed as mean \pm standard deviation (SD) of the indicated
218 number of experiments. Statistical significance was estimated using a Student's *t* test.
219 *P*-values < 0.05 and < 0.01 were considered statistically and highly significant,

220 respectively.

221

222 **Results and Discussion**

223 **Physicochemical Properties and immune activities of SPG-1**


224 1.23 g of SPG-1, in which protein content (21.5 mg/g) was lower than carbohydrate
225 (973.2 mg/g), was yield from 100 g of potato tuber (dry basis). Average molecular
226 weight of SPG-1 was 508.3 kD. The 5 mg of glycoprotein yield per 1 g of fresh tuber
227 that was reported by Kim *et al.*³¹ and the 1.73 mg of potato lectin yield from 100 g of
228 potato tuber that was reported by Pramod and Venkatesh³² are all lower than that of
229 the present study. Nevertheless, the fact that potato lectin is only a portion of
230 glycoproteins and the yield from this study was based on a dry basis should be noted.
231 The average molecular weight of SPG-1 is higher than that of potato lectin (100–110
232 kD)³² and white-skinned sweet potato (*Ipomoea batatas* L.) arabinogalactanprotein
233 (13 kD)⁹. This difference may be attributed to that both lectin and
234 arabinogalactanprotein are only portions of glycoprotein.

235 The SPG-1 solution that was treated with NaOH exhibited more obvious
236 absorbance ($OD_{240nm} = 1.340$) than the untreated compound ($OD_{240nm} = 1.022$). SPG-1
237 was found to contain 15 types of amino acids (date not shown). Compared with the
238 untreated compound, the treated compound showed decreased threonine and serine
239 contents from 2.35 mg/g to 1.90 mg/g, 1.35 mg/g to 0.59 mg/g, respectively.
240 Conversely, alanine increased from 2.30 mg/g to 3.10 mg/g. These results show that
241 SPG-1 consists of O-glycopeptide linkages.³³

242 Agar diffusion plate assay and lymphocyte transformation test were performed to
243 detect serum lysozyme activity and T cell immune response (cpm value), respectively.

244 The serum lysozyme activity and cpm value of SPG-1 group were higher than the NC
 245 group (Figure 1). The activities increased as the doses were increased, when the dose
 246 was 80 mg/kg-d, the difference between the SPG-1 group and NC group were
 247 significantly ($P < 0.05$).

248



249

250 **Fig. 1** SPG-1 and SPG-1-C immune activities

251 Note: NC: normal control group; SPG-1-50: 50 mg/kg-d SPG-1 group; SPG-1-80: 80
 252 mg/kg-d SPG-1 group; SPG-1-C-50: 50 mg/kg-d SPG-1-C group; SPG-1-C-80:
 253 80 mg/kg-d SPG-1-C group; a: $P < 0.05$ compared with NC group.

254

255 Effect of Protease Treatments on SPG-1 T Cell Immune Response

256 SPG-1 was treated with pepsin and trypsin in vitro to determine if T cell immune
 257 response of SPG-1 increases or decreases antigenicity after digestion. The changes in
 258 cpm values are shown in Table 1. The cpm values of SPG-1 decreased with the

259 increase in duration and dose of protease treatment. After treatment with 5.0 g/100 mL
 260 protease for 5 h, the antigenicity activity significantly ($P < 0.05$) changes with respect
 261 to that of the NC and 0 h- treated group. However, both treated groups showed
 262 significantly ($P < 0.01$ or $P < 0.05$) higher activities than that of the NC group. Thus,
 263 pepsin and trypsin slightly decreased SPG-1 immune activity.

264

265 **Table 1.** Effect of protease (pepsin and trypsin) treatments on T cell immune response
 266 (cpm value) of SPG-1.

Enzyme	Content of Enzyme (g/100 mL)	Enzyme-treatment time (h)					
		0	1	2	3	4	5
Pepsin	2.0	1135±65 ^b	1090±52 ^b	1061±56 ^b	903±49 ^b	831±43 ^b	706±42 ^{ac}
	5.0	1135±65 ^b	1060±50 ^b	945±51 ^b	875±48 ^b	770±46 ^{ac}	687±32 ^{ac}
Trypsin	2.0	1135±65 ^b	964±48 ^b	880±52 ^b	784±38 ^b	709±29 ^b	653±36 ^{bc}
	5.0	1135±65 ^b	922±42 ^b	837±38 ^{bd}	760±41 ^{ad}	667±33 ^d	560±29 ^{ac}


267 Note: Cpm value of normal control (NC) group is 250 ± 27 ; a: $P < 0.05$ compared
 268 with NC; b: $P < 0.01$ compared with NC; c: $P < 0.05$ compared with 0 h treatment
 269 group; d: $P < 0.01$ compared with 0 h- treated group.

270

271 **Effect of Glucoamylase Treatment on SPG-1 T Cell Immune Response**

272 T cell immune response of SPG-1 decreased with increase in duration and dose of
 273 glucoamylase treatment (Fig. 2). After treatment with 0.15 and 0.15 g/100 mL
 274 glucoamylase for 5 and 4 h, cpm values of SPG-1 significantly ($P < 0.05$) changed
 275 with respect to that of 0 h-treated group. This finding may be attributed to the ability
 276 of glucoamylase (1,4- α -D-glucanglucohydrolase) to change carbohydrate structures

277 by hydrolyzing α -(1 \rightarrow 4), and, at lower rate, α -(1 \rightarrow 6) glycosidic linkages to remove
 278 glucose units from the nonreducing end of substrates.³⁴ However, the cpm values of
 279 the treated groups were still significantly ($P < 0.01$ or $P < 0.05$) higher than that of the
 280 NC group. Thus, the glucoamylase treatment partly decreased SPG-1 immune activity.
 281



282

283 **Fig. 2** Effect of glucoamylase treatment on T cell immune response (cpm value) of
 284 SPG-1

285 Note: Cpm value of NC group is 246 ± 25 ; G-0.1: 0.1 g/100 mL glucoamylase
 286 concentration; G-0.15: 0.15 g/100 mL glucoamylase concentration; a: $P < 0.05$
 287 compared with NC; b: $P < 0.01$ compared with NC; c: $P < 0.05$ compared with 0 h
 288 treated group.

289

290 **Effect of NaIO₄ Treatment on SPG-1 T Cell Immune Response**

291 The cpm values of NaIO₄ treatment group (293 ± 19) showed no significant difference
292 ($P > 0.05$) with that of the NC group (246 ± 25), while decreased significantly
293 ($P < 0.01$) compared with that of the 0 h - treated group (1108 ± 47). Therefore, NaIO₄
294 oxidation remarkably decreased the T cell immune response of SPG-1. Considering
295 that NaIO₄ could oxidize the carbohydrate portion of SPG-1,³⁵ these findings may
296 indicated that the carbohydrate portion of SPG-1 is the major immune active site.

297

298 **Effect of Acetylation on SPG-1 Immune Activity**

299 The result of the effect of acetylation on SPG-1 immune activity is shown in Table 2.
300 The serum lysozyme activity and T cell immune response of SPG-1 increased when
301 the DS of acetylation increased from 0.28 to 0.67, and subsequently decreased when
302 DS increased from 0.67 to 0.98. Except the high modification group, serum lysozyme
303 activities of modification groups and unmodified control group were significantly
304 ($P < 0.01$ or $P < 0.05$) higher than NC group. The T cell immune responses of
305 modification groups and unmodified control group were significantly ($P < 0.01$) higher
306 than NC group, meanwhile the medium modification group was significantly ($P < 0.05$)
307 higher than unmodified control group. Thus, moderate degree of acetylation increased
308 SPG-1 immune activity. This finding is consistent with previous reports,³⁶ in which
309 biological properties were related to acetylation degree.

310

311

312

313 **Table 2.** Effect of acetylation on SPG-1 immune activity.

Group	Modification degree (DS)	Lysozyme activity ($\mu\text{g/mL}$, n=10)	T cell immune response (cpm)
NC	—	62.56 \pm 14.35	234 \pm 28
Unmodified control	0.00	103.30 \pm 18.22 ^a	1060 \pm 47 ^b
Low modification	0.28	114.52 \pm 16.54 ^b	1245 \pm 68 ^b
Medium modification	0.67	135.45 \pm 20.82 ^b	1897 \pm 79 ^{bc}
High modification	0.98	83.61 \pm 17.25	742 \pm 45 ^b

314 Note: —: not detected; a: $P < 0.05$ compared with NC group; b: $P < 0.01$ compared
 315 with NC group; c: $P < 0.05$ compared with unmodified control group.

316

317 **Effect of Sulfation on SPG-1 Immune Activity**

318 As shown in Table 3, the serum lysozyme activity and T cell immune response of the
 319 unmodified control group significantly ($P < 0.05$) higher than NC group, and the
 320 activities decreased when the DS by sulfation increased. The immune activities of
 321 highly modified group (DS = 1.56) decreased significantly ($P < 0.05$) compared with
 322 that of the unmodified control group. Furthermore, the high modification group
 323 showed no significantly ($P > 0.05$) difference with NC group. These results suggest
 324 that high modification by sulfation led to the loss of SPG-1 immune activity, which
 325 may be attributed to the fact that sulfation is a functionally significant biological
 326 modification of carbohydrates that could alter biological recognition and/or facilitate
 327 rapid protein excretion from the body when present in glycoproteins.³⁷

328

329

330

331 **Table 3.** Effect of sulfation on SPG-1 immune activity


Group	Modification degree (DS)	Lysozyme activity ($\mu\text{g/mL}$, n=10)	T cell immune response (cpm)
NC	—	62.76 \pm 13.48	227 \pm 26
Unmodified control	0.00	101.40 \pm 17.56 ^a	1093 \pm 52 ^b
Low modification	0.32	91.65 \pm 12.78	942 \pm 41 ^b
Medium modification	0.94	78.49 \pm 10.26	709 \pm 39 ^b
High modification	1.56	65.38 \pm 12.76 ^c	392 \pm 31 ^c

332 Note: —: not detected; a: $P < 0.05$ compared with NC group; b: $P < 0.01$ compared
 333 with NC group; c: $P < 0.05$ compared with unmodified control group.


334

335 **Isolation and Purification of SPG-1-C**


336 After DEAE-cellulose-52 anion-exchange column separation, [Fig. 3(A)], 41.4 g of
 337 crude SPG-1-C was yield from 100 g of SPG-1 (dry basis). After further purification
 338 using Sephadex G-100 gel filtration column [Fig. 3(B).], 87.5 g of white SPG-1-C
 339 was yield from 100 g of crude SPG-1-C (dry basis). These results imply that the
 340 yields from SPG-1 and sweet potato to SPG-1-C are 36.2% and 0.45% (w/w, dry
 341 basis), respectively. A single peak was observed in the Sepharose CL-6B gel filtration
 342 column chromatograph [Fig. 3(C)] and a main component of absorbance at 490nm
 343 was obtained by HPLC (RT = 27.52 min, figure not shown), which suggests the
 344 homogeneous state of SPG-1-C. The average molecular weight of SPG-1-C is
 345 392.4 kD.



346



347



348

349 **Fig. 3** Chromatographic purification of SPG-1-C

350 Note: (A) DEAE-cellulose-52 anion-exchange chromatograph of SPG-1-C; (B)

351 Sephadex G-100 gel filtration chromatograph of SPG-1-C; and (C) Sepharose CL-6B

352 gel filtration chromatograph of SPG-1-C.

353

354 **SPG-1-C Immune Activities**

355 Compared with NC group, SPG-1-C increased serum lysozyme activity and cpm

356 value; the activities increased as the doses were increased (see also Fig. 1). The
357 immune activities of SPG-1-C group were higher than those of SPG-1 group at
358 similar dose, but the differences insignificant ($P > 0.05$). Hence, the major immune
359 activity of SPG-1 is attributed to its carbohydrate chain (SPG-1-C), which may be due
360 to the fact that the carbohydrate content of SPG-1 is considerably higher than its
361 protein content and the glycoprotein-glycans are valuable tools for regulating protein
362 structure and function.³⁸

363

364 **Conclusions**

365 SPG-1 increased serum lysozyme activity and T cell immune response correlated with
366 dose. After pepsin, trypsin, and acetylation treatments, the protein portion of SPG-1
367 was changed, resulting to the increased or slight decreased of its immune activities.
368 Furthermore, SPG-1 immune activities decreased or were loss after its carbohydrate
369 portion was modified by glucoamylase, NaIO_4 , and sulfation treatments. SPG-1-C
370 increased immune activities with insignificant difference from SPG-1. Hence, the
371 carbohydrate portion of SPG-1 was found to be its major immune active site. NaIO_4
372 and sulfation treatments should be avoided to maintain the immune function of SPG-1;
373 however, moderate acetylation could be conducted. The results from this study would
374 provide theoretical insights for future improvements on the manufacture of SPG-1.
375 More treatments and immune tests should be conducted in further studies, and the
376 structure of SPG-1 after treatments should be determined to completely explain its
377 immune function.

378

379 **Conflict of interest**

380 On behalf of all authors, the corresponding author states that there is no conflict of
381 interest.

382

383 **Acknowledgments**

384 This work was supported by Chongqing science and technology commission in China
385 (98-5220; 99-5487).

386

387 **References**

- 388 1 Li, B. Wang, C Chi, Y. Gong, J. Tang and H. Luo, *Int. J. Biol. Macromol.*, 2013,
389 **52**, 267-274.
- 390 2 J. Q. Kan, H. Shi, X. Liu and Z. D. Chen, *Food Sci. Biotechnol.*, 2014,
391 **23**,2021-2028.
- 392 3 S. M. Rafiquzzaman, J. M. Lee, R. Ahmed, J. H. Lee, J. M. Kim and I. S. Kong,
393 2015, *Int. J. Food Sci. Tech.*, **50**, 143-150.
- 394 4 M. A. Mesaik, N. Dastagir, N. Uddin, K. Rehman and M. K. Azim, *J. Agr. Food*
395 *Chem.*, 2015, **63**, 177-184.
- 396 5 K. Veena, P. Shanthi and P. Sachdanandam, *Biol. Pharm. Bull.*, 2006, **29**, 565-569.
- 397 6 E. Y. Kim, Y. R. Kim, T. J. Nam and I.S. Kong, *Int. J. Food Sci. Tech.*, 2012, **47**,
398 1020-1027.
- 399 7 J. Guo, L. Liu, X. Lian, L. Li and H. Wu, *Int. J. Biol. Macromol.*, 2014, **67**, 1-6.

- 400 8 S. Ozaki, N. Oki, S. Suzuki and S. Kitamura, *J. Agr. Food Chem.*, 2010, **58**,
401 11593-11599.
- 402 9 N. Oki, S. Nonaka and S. Ozaki, *Biosci. Biotech. Bioch.*, 2011, **75**, 596-598.
- 403 10 S. Seo, S. Karboune, V. Yaylayan and L. L'Hocine, *Process Biochem.*, 2012, **47**,
404 297-304.
- 405 11 S. P. Nie, M.Y. Xie, Z.H. Fu, Y. Q. Wan and A. P. Yan, *Carbohydr. Polym.*, 2008,
406 **71**, 626-633.
- 407 12 Z. Bankowski and N. Howard-Jones, *Biomedical research involving animals:*
408 *proposed international guiding principles*. WHO, 1985, Geneva.
- 409 13 D. Chen, W. J. Yao, X. L. Zhang, X. Q. Han, X. Y. Qu, W. B. Ka, D. G. Sun and X.
410 Z. Wu, *J. Ethnopharmacol.*, 2010, **127**, 702-708.
- 411 14 S. J. Lin, W. N. Tian, H. Li, J. K. Cao and W. B. Jiang, *Int. J. Food Sci. Tech.*,
412 2012, **47**, 2045-2051.
- 413 15 K. B. W. R. Kim, E. J. Song, S. Y. Lee, J. G. Park, L. W. Lee, M. W. Byun and D.
414 H. Ahn, *Radiat. Phys. Chem.*, 2011, **80**, 1258-1262.
- 415 16 R. W. Bailey and J. C. MacRae, *Febs Lett.*, 1973, **31**, 203-204.
- 416 17 X. S. Wang, Q. Dong, J. P. Zuo and J. N. Fang, *Carbohydr. Res.*, 2003, **338**,
417 2393-2402.
- 418 18 K. J. Kumar, C. A. K. Varma and S. G. Panpalia, *Int. J. Biol. Macromol.*, 2014, **69**,
419 108-113.
- 420 19 O. B. Wurzburg, *Modified Starches: Properties and Use*, America: CRC Press,
421 Florida, 1986.

- 422 20 K. Inoue, K. Kawamoto, H. Nakajima, M. Kohno, S. Kadoya and D. Mizuno,
423 *Carbohydr. Res.*, 1983, **115**, 199-208.
- 424 21 K. S. Doigson and R. G. Price, *Biochem. J.*, 1962, **84**, 106-110.
- 425 22 P. X. He, L. J. Geng, Z. Wang, D. B. Mao, J. Z. Wang and C. P. Xu, *Carbohydr.*
426 *Polym.*, 2012, **89**, 17-23.
- 427 23 W. S. Iljin, *Biochemische Zeitschrift*, 1928, **193**, 322-325.
- 428 24 Y. T. Liu, J. Sun, S. Q. Rao, Y. J. Su, J. H. Li, C. M. Li, S. D. Xu and Y. J. Yang,
429 *Food Chem. Toxicol.*, 2013, **62**, 285-291.
- 430 25 W. Jintana, M. Masayuki, K. Pramote and A. Shuji, *Int. J. Food Prop.*, 2013, **16**,
431 974-982.
- 432 26 S. Nie, M. Xie and Y. Wang, *Anal. Bioanal. Chem.*, 2005, **383**, 680-686.
- 433 27 C. Ke, D. Qiao, J. Luo, Z. Li, Y. Sun, H. Ye and X. Zeng, *Int. J. Biol. Macromol.*,
434 2013, **57**, 218-225.
- 435 28 Y. Wu, C. Zhou, L. Song, X. Li, S. Shi, J. Mo, H. Chen, H. Bai, X. Wu, J. Zhao, R.
436 Zhang, X. Hao, H. Sun and Y. Zhao, *J. Ethnopharmacol.*, 2006, **108**, 243-250.
- 437 29 G. J. Yin, G. Jeney, T. Racz, P. Xu, X. Jun and Z. Jeney, *Aquaculture*, 2006, **253**,
438 39-47.
- 439 30 V. V. vonBaehr, W. Mayer, C. Liebenthal, R. V. vonBaehr, W. Bieger and H. D.
440 Volk, *J. Immunol. Methods*, 2001, **251**, 63-71.
- 441 31 Y. S. Kim, Y. H. Lee, H. S. Kim, M. S. Kim, K. W. Hahn, J. H. Ko, H. Joung and J.
442 H. Jeon, *BMC Biotechnol.*, 2008, **8**, 1-9.
- 443 32 S. N. Pramod and Y. P. Venkatesh, *Glycoconjugate J.*, 2006, **23**, 481-488.

- 444 33 Y. Wang, Y. H. Chen, H. Xu, H. M. Luo and R. Z. Jiang, *J. Ethnopharmacol.*,
445 2013, **148**, 946-950.
- 446 34 A. Bagheri, R. Khodarahmi and A. Mostafaie, *Food Chem.*, 2014, **161**, 270-278.
- 447 35 Y. J. Lu, G. N. N. Mbong, P. Liu, C. Chan, Z. L. Cai, D. Weinrich, A. J. Boyle, R.
448 M. Reilly and M. A. Winnik, *Biomacromolecules*, 2014, **15**, 2027-2037.
- 449 36 I. Younes, S. Sellimi, M. Rinaudo, K. Jellouli and M. Nasri, *Int. J. Food*
450 *Microbiol.*, 2014, **185**, 57-63.
- 451 37 H. Jiang, J. Irungu and H. Desaire, *J. Am. Soc. Mass Spectr.*, 2005, **16**,340-348.
- 452 38 H. Geyer and R. Geyer, *BBA -proteins Proteom.*, 2006, **1764**, 1853-1869.